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Abstract
Introduction Recent reports suggest that expression of the
cyclooxygenase 2 (COX-2) enzyme may up-regulate expression
of MDR1/P-glycoprotein (MDR1/P-gp), an exponent of
resistance to cytostatic drugs. The present study aimed at
examining the relationship between the expression of COX-2
and of MDR1/P-gp in a group of breast cancer cases.
Methods Immunohistochemical reactions were performed
using monoclonal antibodies against COX-2 and MDR1/P-gp
on samples originating from 104 cases of primary invasive
breast cancer.
Results COX-2-positive cases were shown to demonstrate
higher expression of MDR1/P-gp (P < 0.0001). The studies also
demonstrate that COX-2 expression was typical for cases of a
higher grade (P = 0.01), a shorter overall survival time (P <
0.0001) and a shorter progression-free time (P < 0.0001). In the
case of MDR1/P-gp, its higher expression characterised cases
of a higher grade (P < 0001), with lymph node involvement (P <
0001), and shorter overall survival (P < 0.0001) and
progression-free time (P < 0.0001).
Conclusion Our studies confirmed the unfavourable prognostic
significance of COX-2 and MDR1/P-gp. We also document a
relationship between COX-2 and MDR1/P-gp, which suggests
that COX-2 inhibitors should be investigated in trials as a
treatment supplementary to chemotherapy of breast cancers.
Introduction
Breast cancer is the most common malignant tumour of
females in the western world [1]. The incidence of breast can-
cer remains high, and its clinical courses are highly variable. It
is of general importance to predict the biology of the tumour
and, thus, the course of the disease in the individual patient to
ensure adequate therapy and patient surveillance [2]. The prin-
cipal therapeutic approach in breast cancer involves surgery.
In advanced cases supplementary therapy is needed, involving
pharmacotherapy and/or radiotherapy. Among the pharmaco-
logical means, tamoxifen used to be applied most frequently,
as well as various chemotherapeutic regimes, including CMF
(cyclophosphamide, methothrexate and 5-fluorouracil), anthra-
cyclines and paclitaxel [3,4]. The main reason for therapeutic
failure in cases of invasive breast cancers involves resistance
to anti-estrogenic treatment and to chemotherapy [5,6]. Iden-
tification of the factors that characterise the resistant cases
would permit immediate treatment of the patients with alterna-
tive therapeutic approaches. These factors could also provide
potential targets for studies on novel therapeutic procedures.
COX = cyclooxygenase; coxibs = cyclooxygenase 2 inhibitors; IRS = immunoreactive score; MDR = multidrug resistance; MDR1/P-gp = MDR1/P-
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Cycloxygenases (COXs) comprise a group of enzymes that
participate in the conversion of arachidonic acid to prostaglan-
dins [7]. COX-2 has been characterised as an unfavourable
prognostic factor in numerous solid tumours [8-10]. We dem-
onstrated previously in breast cancer patients that expression
of COX-2 represents an independent, unfavourable prognos-
tic factor [11]. Numerous in vivo and in vitro studies indicate
that COX-2 inhibitors (coxibs) enhance the efficacy of various
anticancer therapy methods [7]. The effect of coxibs on the
biology of the tumour has been explained by induction of apop-
tosis, inhibition of angiogenesis and by a decreased invasive
potential of tumour cells [7]. COX-2 has also been shown to
up-regulate expression of aromatase [12,13]. In cases of hor-
mone-dependent tumours, such as breast cancer, coxibs
might slow down development of the neoplastic disease by
decreasing aromatase expression and, therefore, decreasing
estrogen secretion. The in vitro studies have demonstrated
also that COX-2 up-regulates expression of MDR1/P-glyco-
protein (MDR1/P-gp) [14], the energy-dependent pump that
participates in the phenomenon of multidrug resistance (MDR)
[5]. MDR1/P-gp efficiently removes drugs and many com-
monly used pharmaceuticals from the lipid bilayer. Confirma-
tion of the relationship between COX-2 and MDR1/P-gp in a
clinical material may open novel perspectives in the therapy of
tumours. Coxibs could be employed as a chemotherapy-sup-
porting treatment, aimed at the inhibition or prevention of the
development of the MDR phenomenon.
The present study aimed to examine the relationship between
the expression of COX-2 and of MDR1/P-gp in primary inva-
sive breast cancers as well as the definition of their prognostic
and predictive values.
Materials and methods
Patients
Immunohistochemical analysis was performed retrospectively
on tissue samples that were taken for routine diagnostic pur-
poses. The cases were selected based on availability of tissue
and were not stratified for known preoperative or pathological
prognostic factors. The study was approved by an Institutional
Review Board (University School of Medicine, Wrocław,
Poland) and the patients gave their informed consent before
their inclusion into the study. A total of 104 patients with pri-
mary invasive breast cancer who were diagnosed in the years
1993 to 1994 in the Lower Silesian Centre of Oncology in
Wrocław, Poland, qualified for the studies. All the patients
were subjected to mastectomy and, subsequently treated with
radiotherapy and/or chemotherapy and/or hormonotherapy
(Table 1). Compliance was monitored by the doctors in
charge. The patients were monitored by periodic medical
check-ups and ultrasonographic and radiological examina-
tions. During the follow-up period, 23 patients (22%) had
recurrent disease and 25 patients (24%) died of the disease.
The mean (median) progression-free survival time was 76
months (range 8 to 103 months), while the mean (median)
overall survival time was 81 months (range 8 to 103 months).
Table 1
Patient and tumour characteristics
Characteristics No. (%)
All patients 104 (100)
Age (years; mean 56.2)
≤ 50 33 (32)
51–60 29 (28)
>60 42 (40)
Menopause
Premenopausal 30 (29)
Postmenopausal 74 (71)
Grade
2 71 (68)
3 33 (32)
pTb
1 17 (16)
2 86 (83)
41  ( 1 )
pNb
0 29 (28)
1 75 (72)
pMb
0 104 (100)
Stageb
I3  ( 3 )
IIa 40 (38)
IIb 60 (58)
IIIb 1 (1)
Histology
Ductal 103 (99)
Scirrhous 1 (1)
Therapya
Tamoxifen 70 (67)
Radiotherapy 51 (49)
Cyclophosphamide/Methotrexate/5-Fluorouracil 28 (27)
Cyclophosphamide/Adriamycin/5-Fluorouracil 1 (1)
Cyclophosphamide/Adriamycin 1 (1)
Progesterone 1 (1)
Letrozol 1 (1)
aSome patients received more than one special treatment.
bAccording to [15]Available online http://breast-cancer-research.com/content/7/5/R862
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Fragments sampled from studied tumours were fixed in 10%
buffered formaline and embedded in paraffin. In every case,
hematoxylin and eosin stained preparations were subjected to
histopathological evaluation by two pathologists. The stage of
the tumours was assessed according to the TNM classifica-
tion system [15]. Tumour grade was estimated according to
Bloom-Richardson and the modification of Elston and Ellis
[16] (Table 1).
Immunohistochemistry
Freshly cut sections (4 µm) of the formalin-fixed, paraffin
embedded tissue were mounted on Superfrost slides (Menzel
Gläser, Braunschweig, Germany), dewaxed with xylene, and
gradually hydrated. Activity of endogenous peroxidase was
blocked by 5 minute exposure to 3% H2O2. All the studied
sections were boiled in Antigen Retrieval Solution (DakoCyto-
mation, Glostrup, Denmark), in the case of COX-2 for 10 min-
utes and in the case of MDR1/P-gp for 15 minutes.
Immunohistochemical reactions were performed using mono-
clonal mouse antibodies against COX-2 (Cayman Chemical
Company, Ann Arbor, MI, USA) at a dilution of 1:2000, mono-
clonal mouse antibodies (clone C219) against MDR1/P-gp
(Alexis Biochemicals, Grünberg, Germany) at a dilution of
Table 2
Evaluation criteria of MDR1/P-gp expression using the immunoreactive score [17]
Percentage of positive cells Points Intensity of reaction Points
No positive cells 0 No reaction 0
<10% 1 Weak reaction 1
10–50% 2 Moderate reaction 2
51–80% 3 Intense reaction 3
>80% 4
MDR1/P-gp, MDR1/P-glycoprotein.
Figure 1
Immunohistochemical localization of cyclooxygenase-2 (red) Immunohistochemical localization of cyclooxygenase-2 (red). The inset 
shows the control reaction with blocking peptide under the same condi-
tions (hematoxylin, ×400).
Figure 2
Immunohistochemical localization of MDR1/P-glycoprotein (red) Immunohistochemical localization of MDR1/P-glycoprotein (red). (a) 
With antibody C219 in breast cancer (showing cytoplasmic and mem-
brane localizations in cancer cells) and healthy human liver (inset) 
(hematoxylin, ×400). (b) With antibody JSB-1 in breast cancer (show-
ing cytoplasmic and membrane localizations in cancer cells) and 
healthy human liver (inset) (hematoxylin, ×400).Breast Cancer Research    Vol 7 No 5    Surowiak et al.
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1:100 and monoclonal mouse antibodies (clone JSB-1)
against MDR1/P-gp (Roche Diagnostics, Mannheim, Ger-
many) at a dilution of 1:100. The antibodies were diluted in
Antibody Diluent with background reducing component
(DakoCytomation). Tested sections were incubated with anti-
bodies for 1 h at room temperature. Subsequent incubations
involved biotinylated antibodies (15 minutes, room tempera-
ture) and streptavidin-biotinylated peroxidase complex (15
minutes, room temperature) using a LSAB+ HRP system
DakoCytomation). NovaRed (Vector Laboratories, Peterbor-
ough, UK) was used as a chromogen (10 minutes, room tem-
perature). All the sections were counterstained with Meyer's
hematoxylin.
Evaluation of reaction intensity
The intensity of immunohistochemical reactions with COX-2
was appraised using a simplified scale. A case was diagnosed
as COX-2 positive (1) when expression was observed in all
tumour cells or in numerous cell clumps, or as COX-2 negative
(0) when no reaction was noted or the reaction was present in
only individual tumour cells (<10%). The intensity of immuno-
histochemical reactions with MDR1/P-gp was appraised
using the semi-quantitative immunoreactive score (IRS) scale
[17], in which the score reflected both the intensity of the reac-
tion and the proportion of positive cells (Table 2). The final
score represented the product of points given for individual
characteristics and ranged between 0 and 12. The intensity of
immunohistochemical reactions was appraised independently
by two pathologists; in doubtful cases, a re-evaluation was
performed using a double-headed microscope.
Control reactions
In each case, control reactions were included, in which spe-
cific antibody was substituted by Primary Mouse Negative
Control (DakoCytomation). Control reactions were also per-
formed for each of the examined antigens. For MDR1/P-gp,
positive controls involved sections of six formalin-fixed and
paraffin-embedded human liver samples (from the archive of
the Chair and Department of Histology and Embryology, Uni-
versity School of Medicine in Poznañ, Poland) for each anti-
body. To evaluate specificity of the COX-2 antibody (Cayman
Chemical Company) we [18] and other investigators [8] per-
formed blocking experiments using the COX-2 blocking pep-
tide (Cayman Chemical Company) according to the
manufacturer's instructions.
Statistical analysis
Statistical analysis of the results took advantage of Statistica
98 PL software (Statsoft, Krakow, Poland). The employed
tests included chi2  test, Spearman's rank correlation and
ANOVA rank Kruskal-Wallis test. Kaplan-Meier's statistics and
log-rank tests were performed using SPSS software (release
10.0; SPSS Inc., Chicago, IL, USA) to estimate the signifi-
cance of differences in survival times. The length of survival
was defined as the time between the primary surgical treat-
ment and diagnosis of a recurrent tumour or death due to the
neoplastic disease. Because the univariate analysis failed to
disclose any significant relationships between studied clinico-
pathological parameters (age, menopausal status, grade and
stage) and overall survival and progression free time in studied
patients (P > 0.05), no multivariate analysis was conducted.
The absence of a relationship between the until now most rec-
ognised and most effective prognostic factors [19] and patient
survival time resulted most probably from the highly uniform
character of the examined group of patients. As many as 96%
of the examined patients represented the stage II (UICC) [15].
The uniform character of the group allowed a more unequivo-
cal evaluation of the effect of the intensity of expression of the
studied protein on the survival time of the patients.
Results
Immunostaining in control preparations and in breast 
cancers
Immunostaining for COX-2 occurred in a cytoplasmic localiza-
tion and was of varying intensity among individual cases (Fig.
Figure 3
Correlation between cyclooxygenase-2 (COX-2) and MDR1/P-glyco- protein (MDR1/P-gp) expression Correlation between cyclooxygenase-2 (COX-2) and MDR1/P-glyco-
protein (MDR1/P-gp) expression. (a) Correlation between COX-2 and 
MDR1/P-gp expression detected with antibody C219. (b) Correlation 
between COX-2 and MDR1/P-gp expression detected with antibody 
JSB-1 in breast cancers. Cases with COX-2 expression show higher 
MDR1/P-gp expression (ANOVA Kruskall-Wallis rank test, P < 0.001).Available online http://breast-cancer-research.com/content/7/5/R862
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1). In six COX-2 positive cases, we performed blocking exper-
iments using the COX-2 blocking peptide, as described previ-
ously [18]. We found no staining in control preparations (Fig.
1). Expression of COX-2 was noted in 46 cases (44%).
Immunostaining for MDR1/P-gp occurred in membranes in
samples of healthy human liver and in the cytoplasm and mem-
branes in breast cancers, and was of varying intensity among
individual cases (Fig. 2a,b). The mean overall immunoreactivity
score for MDR1/P-gp expression detected with antibody
C219 was 3.45 ± 3.49 standard deviation (range: 0 IRS to 12
IRS) and with antibody JSB-1 was 3.34 ± 3.49 standard devi-
ation (range: 0 IRS to 12 IRS). We found a strict positive cor-
relation between expression with C219 and JSB-1
(Spearman's rank correlation, R = 0.99, P < 0.001).
Using the ANOVA rank Kruskal-Wallis test, we examined the
relationship between COX-2 expression and the overall immu-
noreactivity score of MDR1/P-gp expression. We found that
the overall immunoreactivity score of MDR1/P-gp expression
with C219 and JSB-1 was significantly higher in cases show-
ing expression of COX-2 (P < 0.0001) (Fig. 3a,b; Table 3).
Chi2 tests were also used to analyse the relationships between
the intensity of COX-2 and MDR1/P-gp expression on the one
hand and the grade, stage, pT (UICC) [15], pN (UICC) [15]
and menopausal status of studied patients on the other. We
found that at a grade of G3, a significantly higher proportion of
cases manifested COX-2 expression compared to patients
with a G2 grade (Table 4). The pN1 cases were also shown to
exhibit a higher overall immunoreactivity score for C219 and
JSB-1 compared to pN0 cases (Table 4); similarly, cases with
a G3 grade showed a higher overall immunoreactivity score for
C219 and JSB-1 compared to those with a G2 grade (Table
4).
COX-2 and MDR1/P-gp expression and patient survival
Kaplan-Meier statistics were used to analyse overall survival
time and progression-free survival. In the entire study group,
the COX-2 positive cases manifested a significantly shorter
overall survival time and progression-free survival compared to
COX-2 negative cases (Fig. 4c,f). Cases with an overall C219
and JSB-1 immunoreactivity score between 0 and 3 were also
shown to manifest a significantly extended overall survival time
and progression-free survival compared to cases with an over-
all C219 and JSB-1 immunoreactivity score between 4 and 12
(Fig. 4a,b,d,e). The same results were obtained in the sub-
group of patients that, following surgery, were treated only
with chemotherapy (Fig. 5a–f).
Discussion
We have described the expression of COX-2 and MDR1/P-gp
proteins detected by immunohistochemistry in primary inva-
sive breast cancers. Following the recommendations of the St
Judge MDR Workshop on 'Methods to Detect MDR1/P-gp-
associated Multidrug Resistance' [20], we have used two dif-
ferent monoclonal antibodies (C219 and JSB-1) directed
against MDR1/P-gp. We found a strict positive correlation
between MDR1/P-gp expression detected with C219 and
JSB-1. We have confirmed that the studied proteins are
Table 3
Relationship between COX-2 and MDR1/P-gp (detected with C219 or JSB-1 antibodies) expression (Chi2-Test, P < 0.001)
COX-2 positive cases COX-2 negative cases Sum
Entire study group (n = 104)
C219 low [IRS 0–3] 56 5 61
C219 high [IRS 4–12] 2 41 43
Sum 58 46 104
JSB-1 low [IRS 0–3] 55 4 59
JSB-1 high [IRS 4–12] 3 42 45
Sum 58 46 104
Patients postoperatively treated only with chemotherapy (n = 28)
C219 low [IRS 0–3] 13 1 14
C219 high [IRS 4–12] 1 13 14
Sum 14 14 28
JSB-1 low [IRS 0–3] 12 1 13
JSB-1 high [IRS 4–12] 2 13 15
Sum 14 14 28
COX-2, cyclooxygenase-2; MDR1/P-gp, MDR1/P-glycoprotein; IRS, immunoreactive score [17].Breast Cancer Research    Vol 7 No 5    Surowiak et al.
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expressed in a subset of breast cancers [11,21-23]. No rela-
tionship was discovered between COX-2 expression and
such clinicopathological traits as pT, pN, stage or menopausal
status. A higher proportion of COX-2 positive cases was
noted in G3 compared to G2 patients. Previously, we noted
that COX-2 expression was significantly associated with
higher grade, lymph node status and larger tumour size [11].
Ristimäki  et al. [21] described COX-2 expression using a
tissue microarray in 1,576 cases of invasive breast cancer.
They demonstrated that elevated COX-2 expression was
associated with a large tumour size and high histological
grade. In the present study, we have corroborated the positive
correlation between COX-2 expression and the unfavourable
clinicopathological prognostic indices in another group of
patients. We have shown that a higher overall MDR1/P-gp
immunoreactivity score is associated with lymph node involve-
ment and a higher histological grade. Numerous authors have
demonstrated a positive correlation between MDR1/P-gp
expression and tumour stage [24,25]. To our knowledge, this
study demonstrates for the first time a significant positive cor-
relation between overall MDR1/P-gp immunoreactivity score
and grade of breast cancer tumours. Thus, expression of
MDR1/P-gp is typical for the less differentiated cases of
breast cancer.
Expression of COX-2 in tumour cells represents an unfavour-
able prognostic factor in numerous tumours [9,10]. We [11]
and other authors [21] have previously demonstrated that
COX-2 represents an independent unfavourable prognostic
factor in breast cancers. In this study, we have shown that
COX-2 positive cases exhibit a significantly shorter overall sur-
vival and progression-free time in the entire study group and in
a group of patients treated postoperatively with cytostatic
drugs. Thus, we have confirmed the previously described
observations that COX-2 expression in breast cancer is a neg-
ative prognostic factor.
The unfavourable prognostic significance of MDR1/P-gp
expression has been documented in several tumours, includ-
ing breast cancer [24,26-29]. Most of the studies have
described the negative prognostic significance in breast
cancer cases treated with chemotherapy. Few of the studies
have suggested that MDR1/P-gp may also participate in the
resistance to hormonal therapy [28]. In our study, we have
Table 4
Relationship between COX-2 and MDR1/P-gp (detected with C219 or JSB-1 antibodies) expression and clinicopathologic factors
Characteristics No. of patients (%)
COX-2 
positive
COX-2 
negative
P value 
Chi2 test
C219 high 
(IRS 4–12)
C219 low 
(IRS 0–3)
P value 
Chi2 test
JSB-1 high 
(IRS 4–12)
JSB-1 low 
(IRS 0–3)
P value 
Chi2 test
pT
1 8 (8) 9 (9) 7 (7) 10 (10) 8 (8) 9 (9)
2 37 (36) 49 (47) 35 (34) 51 (49) 36 (35) 50 (48)
4 1 (1) 0 (0) 0.4954 1 (1) 0 (0) 0.7869 1 (1) 0 (0) 0.6306
pN
0 10 (10) 19 (18) 11 (11) 18 (17) 11 (11) 18 (17)
1 36 (35) 39 (37) 0.2117 32 (31) 43 (41) <0.001 34 (33) 41 (39) <0.001
Stage
I 1 (1) 2 (2) 1 (1) 2 (2) 1 (1) 2 (2)
IIa 16 (15) 24 (23) 16 (15) 24 (23) 17 (16) 23 (22)
IIb 28 (27) 32 (31) 25 (24) 35 (34) 29 (28) 31 (30)
IIIb 1 (1) 0 (0) 0.6628 1 (1) 0 (0) 0.5915 1 (1) 0 (0) 0.5874
Grade
2 26 (25) 45 (43) 25 (24) 46 (44) 26 (25) 45 (43)
3 20 (19) 13 (13) 0.0135 18 (17) 15 (14) <0.001 19 (18) 14 (13) < 0.001
Menopause
Praemenopausal 12 (12) 18 (17) 13 (13) 17 (16) 14 (13) 16 (15)
Postmenopausal 34 (33) 40 (38) 0.4553 30 (30) 44 (42) 0.8307 31 (30) 43 (41) 0.9703
COX-2, cyclooxygenase-2; MDR1/P-gp, MDR1/P-glycoprotein; IRS, immunoreactive score.Available online http://breast-cancer-research.com/content/7/5/R862
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shown, both in the entire group of patients (in whom surgery
was followed by hormonal therapy and/or radiotherapy) and in
the group of patients postoperatively treated with chemother-
apy, that patients with a higher overall MDR1/P-gp immunore-
activity score exhibited a significantly shorter overall survival
and progression-free time. As shown by our data, expression
of MDR1/P-gp may not only be linked to resistance to cyto-
static drugs but, considering that the higher overall MDR1/P-
gp immunoreactivity score is associated with lymph node
involvement and higher histological grade, may also represent
an unfavourable prognostic factor independent of the applied
therapy.
Several reports have suggested that elevated expression of
COX-2 may stimulate expression of MDR1/P-gp. Such a phe-
nomenon has been demonstrated, for example, in mesangial
cells of rat kidneys, in which transfection with the COX-2 gene
was followed by an increase in MDR1/P-gp expression [14],
and in cells of the gastric mucosa during infection with Helico-
bacter pylori [30]. Ratnasinghe et al. [31] have described a
positive correlation between COX-2 and MDR1/P-gp
expression in breast cancer cases and cell lines. In this study,
we confirm that a higher overall MDR1/P-gp immunoreactivity
score is typical for COX-2 positive breast cancer cases. To
our knowledge, this study demonstrates for the first time a
negative prognostic significance of COX-2 and MDR1/P-gp
coexpression in breast cancers. The data suggest that clinical
studies should be performed on coxibs in chemotherapy-sup-
porting treatment. Apart from their anti-tumour effects, these
drugs might prevent the development of, or decrease the
intensity of, the already existing MDR phenomenon.
Conclusion
We have shown the predictive significance of the immunohis-
tochemical estimation of COX-2 and MDR1/P-gp expression
in human breast cancers. We found a positive correlation
Figure 4
Kaplan-Meier analysis of the complete group of 104 breast cancer patients Kaplan-Meier analysis of the complete group of 104 breast cancer patients. (a) Patients with a lower overall immunoreactivity score for MDR1/P-
glycoprotein (MDR1/P-gp) expression detected with antibody C219 exhibit significantly longer overall survival. (b) Patients with a lower overall 
immunoreactivity score for MDR1/P-gp expression detected with antibody JSB-1 exhibit significantly longer overall survival. (c) Cyclooxygenase-2 
(COX-2) negative cases exhibit significantly longer overall survival. (d) Patients with a lower overall immunoreactivity score for MDR1/P-gp expres-
sion detected with antibody C219 exhibit significantly longer progression-free survival. (e) Patients with a lower overall immunoreactivity score for 
MDR1/P-gp expression detected with antibody JSB-1 exhibit significantly longer progression-free survival. (f) COX-2 negative cases exhibit signifi-
cantly longer progression-free survival.Breast Cancer Research    Vol 7 No 5    Surowiak et al.
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between COX-2 and MDR1/P-gp expression and demon-
strated that COX-2 and MDR1/P-gp are unfavourable
prognostic factors in breast cancers and unfavourable predic-
tive factors in chemotherapy-treated breast cancer cases.
Clinical studies should be performed on coxibs as a support-
ing treatment in breast cancer chemotherapy.
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